FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201468520> ?p ?o ?g. }

• W3201468520 endingPage "1402" @default.
• W3201468520 startingPage "1391" @default.
• W3201468520 abstract "Both continuous therapy with acalabrutinib and fixed-duration therapy with venetoclax-obinutuzumab are effective for previously untreated chronic lymphocytic leukaemia. We hypothesised that frontline time-limited, minimal residual disease (MRD)-guided triplet therapy with acalabrutinib, venetoclax, and obinutuzumab would induce deep (ie, more patients with undetectable MRD) and durable remissions.In this open-label, single-arm, investigator-sponsored, phase 2 study, patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma were recruited from two academic hospitals in Boston, MA, USA. Eligible patients were aged 18 years or older, with an Eastern Cooperative Oncology Group performance status of 0-2, and were treatment naive. Patients were treated in 28 day cycles. Acalabrutinib monotherapy was given orally at 100 mg twice daily for cycle 1, then combined for six cycles with intravenous obinutuzumab (100 mg on cycle 2 day 1, 900 mg on day 2, 1000 mg on day 8, and 1000 mg on day 15 and on day 1 of cycles 3-7); and from the beginning of cycle 4, oral venetoclax was dosed daily using an accelerated ramp-up from 20 mg on day 1 to 400 mg by day 22 and continued at this dose thereafter. Patients continued on acalabrutinib 100 mg twice daily and venetoclax 400 mg once daily until day 1 of cycle 16 or day 1 of cycle 25. If the patient had undetectable MRD in the bone marrow they were given the option to discontinue therapy at the start of cycle 16 (if also in complete remission) or at the start of cycle 25 (if at least in partial remission). The primary endpoint was complete remission with undetectable MRD in the bone marrow (defined as <1 chronic lymphocytic leukaemia cell per 10 000 leucocytes as measured by four-colour flow cytometry), at cycle 16 day 1. Safety and activity endpoints were assessed in all patients who received at least one dose of any study drug. This study is registered with ClinicalTrials.gov, NCT03580928, and is ongoing.Between Aug 2, 2018, and May 23, 2019, 37 patients with chronic lymphocytic leukaemia were enrolled and all received at least one dose of any study drug. The median age of patients was 63 years (IQR 57-70), and ten (27%) were female and 27 (73%) were male. Median follow-up was 27·6 months (IQR 25·1-28·2). At cycle 16 day 1, 14 (38% [95% CI 22-55]) of 37 participants had a complete remission with undetectable MRD in the bone marrow. The most common grade 3 or 4 haematological adverse event was neutropenia (16 [43%] of 37 patients). The most common grade 3-4 non-haematological adverse events were hyperglycaemia (three [8%]) and hypophosphataemia (three [8%]). Serious adverse events occurred in nine (24%) patients; the most common was neutropenia in three (8%) patients. There have been no deaths on study.Acalabrutinib, venetoclax, and obinutuzumab is a highly active and well tolerated frontline therapy for chronic lymphocytic leukaemia. Although the primary endpoint of this study was not met, the high proportion of patients who had undetectable MRD in the bone marrow supports further investigation of this regimen, which is being tested against acalabrutinib-venetoclax and chemoimmunotherapy in an ongoing phase 3 study (NCT03836261).AstraZeneca and a Dana-Farber Cancer Institute Collaborative Award." @default.
• W3201468520 created "2021-09-27" @default.
• W3201468520 creator A5001243668 @default.
• W3201468520 creator A5002386517 @default.
• W3201468520 creator A5010499534 @default.
• W3201468520 creator A5012072790 @default.
• W3201468520 creator A5016570475 @default.
• W3201468520 creator A5016770040 @default.
• W3201468520 creator A5017380326 @default.
• W3201468520 creator A5021158149 @default.
• W3201468520 creator A5037526878 @default.
• W3201468520 creator A5037613158 @default.
• W3201468520 creator A5044588871 @default.
• W3201468520 creator A5053410437 @default.
• W3201468520 creator A5059821588 @default.
• W3201468520 creator A5063755644 @default.
• W3201468520 creator A5069822416 @default.
• W3201468520 creator A5077671733 @default.
• W3201468520 creator A5085801543 @default.
• W3201468520 creator A5088077600 @default.
• W3201468520 date "2021-10-01" @default.
• W3201468520 modified "2023-10-16" @default.
• W3201468520 title "Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study" @default.
• W3201468520 cites W2134138207 @default.
• W3201468520 cites W2153923291 @default.
• W3201468520 cites W2192121806 @default.
• W3201468520 cites W2369297677 @default.
• W3201468520 cites W2573476619 @default.
• W3201468520 cites W2580821712 @default.
• W3201468520 cites W2790385276 @default.
• W3201468520 cites W2792666902 @default.
• W3201468520 cites W2886452066 @default.
• W3201468520 cites W2902484351 @default.
• W3201468520 cites W2902706178 @default.
• W3201468520 cites W2946882253 @default.
• W3201468520 cites W2948436219 @default.
• W3201468520 cites W2982882523 @default.
• W3201468520 cites W3013074397 @default.
• W3201468520 cites W3016538158 @default.
• W3201468520 cites W3033943641 @default.
• W3201468520 cites W3038483739 @default.
• W3201468520 cites W3049430822 @default.
• W3201468520 cites W3082899459 @default.
• W3201468520 cites W3095280492 @default.
• W3201468520 cites W3095298252 @default.
• W3201468520 cites W3095746683 @default.
• W3201468520 cites W3095913856 @default.
• W3201468520 cites W3096240278 @default.
• W3201468520 cites W3097014789 @default.
• W3201468520 cites W3134524629 @default.
• W3201468520 cites W3185756680 @default.
• W3201468520 doi "https://doi.org/10.1016/s1470-2045(21)00455-1" @default.
• W3201468520 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34534514" @default.
• W3201468520 hasPublicationYear "2021" @default.
• W3201468520 type Work @default.
• W3201468520 sameAs 3201468520 @default.
• W3201468520 citedByCount "45" @default.
• W3201468520 countsByYear W32014685202021 @default.
• W3201468520 countsByYear W32014685202022 @default.
• W3201468520 countsByYear W32014685202023 @default.
• W3201468520 crossrefType "journal-article" @default.
• W3201468520 hasAuthorship W3201468520A5001243668 @default.
• W3201468520 hasAuthorship W3201468520A5002386517 @default.
• W3201468520 hasAuthorship W3201468520A5010499534 @default.
• W3201468520 hasAuthorship W3201468520A5012072790 @default.
• W3201468520 hasAuthorship W3201468520A5016570475 @default.
• W3201468520 hasAuthorship W3201468520A5016770040 @default.
• W3201468520 hasAuthorship W3201468520A5017380326 @default.
• W3201468520 hasAuthorship W3201468520A5021158149 @default.
• W3201468520 hasAuthorship W3201468520A5037526878 @default.
• W3201468520 hasAuthorship W3201468520A5037613158 @default.
• W3201468520 hasAuthorship W3201468520A5044588871 @default.
• W3201468520 hasAuthorship W3201468520A5053410437 @default.
• W3201468520 hasAuthorship W3201468520A5059821588 @default.
• W3201468520 hasAuthorship W3201468520A5063755644 @default.
• W3201468520 hasAuthorship W3201468520A5069822416 @default.
• W3201468520 hasAuthorship W3201468520A5077671733 @default.
• W3201468520 hasAuthorship W3201468520A5085801543 @default.
• W3201468520 hasAuthorship W3201468520A5088077600 @default.
• W3201468520 hasConcept C126322002 @default.
• W3201468520 hasConcept C143998085 @default.
• W3201468520 hasConcept C2777607594 @default.
• W3201468520 hasConcept C2777938653 @default.
• W3201468520 hasConcept C2778461978 @default.
• W3201468520 hasConcept C2779675984 @default.
• W3201468520 hasConcept C2779823535 @default.
• W3201468520 hasConcept C2780007613 @default.
• W3201468520 hasConcept C71924100 @default.
• W3201468520 hasConcept C90924648 @default.
• W3201468520 hasConceptScore W3201468520C126322002 @default.
• W3201468520 hasConceptScore W3201468520C143998085 @default.
• W3201468520 hasConceptScore W3201468520C2777607594 @default.
• W3201468520 hasConceptScore W3201468520C2777938653 @default.
• W3201468520 hasConceptScore W3201468520C2778461978 @default.
• W3201468520 hasConceptScore W3201468520C2779675984 @default.
• W3201468520 hasConceptScore W3201468520C2779823535 @default.
• W3201468520 hasConceptScore W3201468520C2780007613 @default.
• W3201468520 hasConceptScore W3201468520C71924100 @default.

• next